Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Completed 8Unknown 4Terminated 3Recruiting 3Active not recruiting 3

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 3Gynecologic 3Breast 3Genitourinary 2Gastrointestinal 2CNS 2Thoracic 1Plasma cell 1Other solid neoplasm 1

Conditions

Leukoplakia, Oral 2Erythroplasia 2Squamous Cell Carcinoma of Head and Neck 1Mouth Neoplasms 1Hyperplasia 1

Interventions

pembrolizumab 66Cisplatin 55Radiotherapy, Intensity-Modulated 28Carboplatin 27Nivolumab 26Paclitaxel 21Magnetic Resonance Spectroscopy 21Radiotherapy 20Cetuximab 16Specimen Handling 15Docetaxel 15Radiation 14Gemcitabine 13Fluorouracil 12Biopsy 12durvalumab 11Platinum 11Taxes 10Drug Therapy 101,2-diaminocyclohexaneplatinum II citrate 10Surveys and Questionnaires 9Capecitabine 9trametinib 8tislelizumab 6lenvatinib 6dabrafenib 6cemiplimab 6atezolizumab 6Radiosurgery 6Ipilimumab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Active not recruiting × Metformin × Head & Neck × Clear all
NCT04414540 2026-05-08

Combining Pembrolizumab and Metformin in Metastatic Head and Neck Cancer Patients

University of Cincinnati

Phase 2 Active not recruiting
21 enrolled 12 charts
Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT05237960 2026-04-20

Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia

University of Arizona

Phase 2 Active not recruiting
34 enrolled
Head & Neck

Erythroplasia, Leukoplakia, Oral

NCT02581137 2026-04-13

Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion

National Cancer Institute (NCI)

Phase 2 Active not recruiting
26 enrolled 10 charts
Head & Neck

Erythroplasia, Hyperplasia, Leukoplakia, Oral, Mouth Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡